Literature DB >> 26205821

PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.

Jennifer D Kubic1, Jason W Lui1, Elizabeth C Little1, Anton E Ludvik1, Sasank Konda1, Ravi Salgia2, Andrew E Aplin3, Deborah Lang4.   

Abstract

Metastatic melanoma is an aggressive and deadly disease. The chemokine receptor CXCR4 is active in melanoma metastasis, although the mechanism for the promotion and maintenance of CXCR4 expression in these cells is mostly unknown. Here, we find melanoma cells express two CXCR4 isoforms, the common version and a variant that is normally restricted to cells during development or to mature blood cells. CXCR4 expression is driven through a highly conserved intronic enhancer element by the transcription factors PAX3 and FOXD3. Inhibition of these transcription factors slows melanoma cell growth, migration, and motility, as well as reduces CXCR4 expression. Overexpression of these transcription factors drives the production of increased CXCR4 levels. Loss of PAX3 and FOXD3 transcription factor activity results in a reduction in cell motility, migration, and chemotaxis, all of which are rescued by CXCR4 overexpression. Here, we discover a molecular pathway wherein PAX3 and FOXD3 promote CXCR4 gene expression in melanoma.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA-protein interaction; gene expression; gene regulation; melanoma; transcription factor

Mesh:

Substances:

Year:  2015        PMID: 26205821      PMCID: PMC4571945          DOI: 10.1074/jbc.M115.670976

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  PAX3 is expressed in human melanomas and contributes to tumor cell survival.

Authors:  F A Scholl; J Kamarashev; O V Murmann; R Geertsen; R Dummer; B W Schäfer
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

2.  TBX2 expression is regulated by PAX3 in the melanocyte lineage.

Authors:  Fang Liu; Juxiang Cao; Jinghu Lv; Liang Dong; Eric Pier; George X Xu; Rui-an Wang; Zhixiang Xu; Colin Goding; Rutao Cui
Journal:  Pigment Cell Melanoma Res       Date:  2012-11-21       Impact factor: 4.693

3.  CXCR7 mediates SDF1-induced melanocyte migration.

Authors:  Eunkyung Lee; Jiyeon Han; Kwangmi Kim; Hyunjung Choi; Eun-Gyung Cho; Tae Ryong Lee
Journal:  Pigment Cell Melanoma Res       Date:  2012-10-26       Impact factor: 4.693

4.  The two human CXCR4 isoforms display different HIV receptor activities: consequences for the emergence of X4 strains.

Authors:  Charline Duquenne; Christina Psomas; Sandrine Gimenez; Adeline Guigues; Marie-Josée Carles; Claudine Barbuat; Jean-Philippe Lavigne; Albert Sotto; Jacques Reynes; Paul Guglielmi; Clément Mettling; Vincent François; Pierre Corbeau
Journal:  J Immunol       Date:  2014-09-17       Impact factor: 5.422

5.  PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression.

Authors:  Shujie He; Caiyun G Li; Lynn Slobbe; Amy Glover; Elaine Marshall; Bruce C Baguley; Michael R Eccles
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

6.  A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.

Authors:  Elise Bonvin; Paola Falletta; Heather Shaw; Veronique Delmas; Colin R Goding
Journal:  Mol Cell Biol       Date:  2012-09-17       Impact factor: 4.272

7.  Xmrk-induced melanoma progression is affected by Sdf1 signals through Cxcr7.

Authors:  Daniel Liedtke; Isabell Erhard; Keiko Abe; Makoto Furutani-Seiki; Hisato Kondoh; Manfred Schartl
Journal:  Pigment Cell Melanoma Res       Date:  2013-11-27       Impact factor: 4.693

8.  Cooperative interactions between paired domain and homeodomain.

Authors:  S Jun; C Desplan
Journal:  Development       Date:  1996-09       Impact factor: 6.868

9.  Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.

Authors:  G O'Boyle; I Swidenbank; H Marshall; C E Barker; J Armstrong; S A White; S P Fricker; R Plummer; M Wright; P E Lovat
Journal:  Br J Cancer       Date:  2013-03-28       Impact factor: 7.640

10.  PAX3 and ETS1 synergistically activate MET expression in melanoma cells.

Authors:  J D Kubic; E C Little; J W Lui; T Iizuka; D Lang
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

View more
  12 in total

1.  PAX3 Promotes Cell Migration and CXCR4 Gene Expression in Neural Crest Cells.

Authors:  Man Xu; Yongle Li; Jinfeng Du; Hengrong Lin; Sixian Cao; Zuming Mao; Ronghua Wu; Mei Liu; Yan Liu; Qiyou Yin
Journal:  J Mol Neurosci       Date:  2017-11-13       Impact factor: 3.444

2.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.

Authors:  Yan Wang; Ying Xie; David Oupický
Journal:  Curr Pharmacol Rep       Date:  2016-01-04

Review 3.  Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer.

Authors:  Ying Xie; Yazhe Wang; Jing Li; Yu Hang; David Oupický
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

4.  Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer.

Authors:  Elizabeth C Little; Jennifer D Kubic; Ravi Salgia; Paul J Grippo; Deborah Lang
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

5.  Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Authors:  Ravi Salgia; R Waide Weaver; Michael McCleod; John R Stille; S Betty Yan; Stephanie Roberson; John Polzer; Amy Flynt; Eyas Raddad; Victoria L Peek; Sameera R Wijayawardana; Suzane L Um; Steve Gross; Mark C Connelly; Carrie Morano; Madeline Repollet; Renouard Sanders; Kurt Baeten; David D'Haese; David R Spigel
Journal:  Invest New Drugs       Date:  2017-03-15       Impact factor: 3.850

6.  Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis.

Authors:  Jun Zheng; Hui Li; Liying He; Yiming Huang; Jianye Cai; Liang Chen; Chaorong Zhou; Hongyuan Fu; Tongyu Lu; Yingcai Zhang; Jia Yao; Yang Yang
Journal:  Cell Prolif       Date:  2018-12-10       Impact factor: 6.831

7.  From Pioneer to Repressor: Bimodal foxd3 Activity Dynamically Remodels Neural Crest Regulatory Landscape In Vivo.

Authors:  Martyna Lukoseviciute; Daria Gavriouchkina; Ruth M Williams; Tatiana Hochgreb-Hagele; Upeka Senanayake; Vanessa Chong-Morrison; Supat Thongjuea; Emmanouela Repapi; Adam Mead; Tatjana Sauka-Spengler
Journal:  Dev Cell       Date:  2018-12-03       Impact factor: 12.270

8.  FOXD3 may be a new cellular target biomarker as a hypermethylation gene in human ovarian cancer.

Authors:  Gui-Fang Luo; Chang-Ye Chen; Juan Wang; Hai-Yan Yue; Yong Tian; Ping Yang; Yu-Kun Li; Yan Li
Journal:  Cancer Cell Int       Date:  2019-02-28       Impact factor: 5.722

9.  PAX3 is a biomarker and prognostic factor in melanoma: Database mining.

Authors:  Yong Liu; Shengnan Cui; Wenbin Li; Yiding Zhao; Xiaoning Yan; Jianqin Xu
Journal:  Oncol Lett       Date:  2019-03-18       Impact factor: 2.967

10.  Identification of key genes involved in the pathogenesis of cutaneous melanoma using bioinformatics analysis.

Authors:  Jianqin Chen; Wen Sun; Nian Mo; Xiangjun Chen; Lihong Yang; Shaozhong Tu; Siwen Zhang; Jing Liu
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.